Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...
After publication of potentially practice-changing clinical trials, identified through ASCO's signals approach to updating, an updated systematic review was performed for two guideline questions: ...
Methods We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses ...
Understand key factors influencing hemophilia A treatment decisions and explore the impact of prophylactic vs on-demand therapy on efficacy, safety, and patient outcomes, including joint health, ...
Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...
Valoctocogene roxaparvovec delivers a B-domain–deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a ...
Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...
If approved, Mim8 (denecimig) would offer the flexibility of treatment with a single-use, prefilled disposable pen injector with dosing options including once every month, once every two weeks, and ...
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results